JK500 cell injection
/ Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Sciences, Escure Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
November 28, 2022
Safety and Preliminary Efficacy of JK500 Cell Injection in Relapsed/Refractory Pediatric Acute Myeloid Leukemia
(clinicaltrials.gov)
- P1 | N=12 | Recruiting | Sponsor: Institute of Hematology & Blood Diseases Hospital | Not yet recruiting ➔ Recruiting
Enrollment open • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • Pediatrics
August 29, 2022
Safety and Preliminary Efficacy of JK500 Cell Injection in Relapsed/Refractory Pediatric Acute Myeloid Leukemia
(clinicaltrials.gov)
- P1 | N=12 | Not yet recruiting | Sponsor: Institute of Hematology & Blood Diseases Hospital
New P1 trial • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • Pediatrics
1 to 2
Of
2
Go to page
1